 |
|
Long-Chain  -3 Fatty Acids for Indicated Prevention of Psychotic DisordersA Randomized, Placebo-Controlled Trial
G. Paul Amminger, MD;
Miriam R. Schäfer, MD;
Konstantinos Papageorgiou, MD;
Claudia M. Klier, MD;
Sue M. Cotton, PhD;
Susan M. Harrigan, MSc;
Andrew Mackinnon, PhD;
Patrick D. McGorry, MD, PhD;
Gregor E. Berger, MD
Arch Gen Psychiatry. 2010;67(2):146-154.
Context The use of antipsychotic medication for the prevention of psychotic disorders is controversial. Long-chain  -3 (omega-3) polyunsaturated fatty acids (PUFAs) may be beneficial in a range of psychiatric conditions, including schizophrenia. Given that -3 PUFAs are generally beneficial to health and without clinically relevant adverse effects, their preventive use in psychosis merits investigation.
Objective To determine whether -3 PUFAs reduce the rate of progression to first-episode psychotic disorder in adolescents and young adults aged 13 to 25 years with subthreshold psychosis.
Design Randomized, double-blind, placebo-controlled trial conducted between 2004 and 2007.
Setting Psychosis detection unit of a large public hospital in Vienna, Austria.
Participants Eighty-one individuals at ultra-high risk of psychotic disorder.
Interventions A 12-week intervention period of 1.2-g/d -3 PUFA or placebo was followed by a 40-week monitoring period; the total study period was 12 months.
Main Outcome Measures The primary outcome measure was transition to psychotic disorder. Secondary outcomes included symptomatic and functional changes. The ratio of -6 to -3 fatty acids in erythrocytes was used to index pretreatment vs posttreatment fatty acid composition.
Results Seventy-six of 81 participants (93.8%) completed the intervention. By study's end (12 months), 2 of 41 individuals (4.9%) in the -3 group and 11 of 40 (27.5%) in the placebo group had transitioned to psychotic disorder (P = .007). The difference between the groups in the cumulative risk of progression to full-threshold psychosis was 22.6% (95% confidence interval, 4.8-40.4). -3 Polyunsaturated fatty acids also significantly reduced positive symptoms (P = .01), negative symptoms (P = .02), and general symptoms (P = .01) and improved functioning (P = .002) compared with placebo. The incidence of adverse effects did not differ between the treatment groups.
Conclusions Long-chain -3 PUFAs reduce the risk of progression to psychotic disorder and may offer a safe and efficacious strategy for indicated prevention in young people with subthreshold psychotic states.
Trial Registration clinicaltrials.gov Identifier: NCT00396643
Author Affiliations: Department of Child and Adolescent Psychiatry, Medical University of Vienna, Vienna, Austria (Drs Amminger, Schäfer, Papageorgiou, and Klier); Orygen Research Centre, Centre for Youth Mental Health, The University of Melbourne, Melbourne, Australia (Drs Amminger, Cotton, Mackinnon, and McGorry and Ms Harrigan); and Department of Research and Education, The Schlössli Clinic, Oetwil am See, Switzerland (Dr Berger).
 CiteULike  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
This Month in Archives of General Psychiatry
Arch Gen Psychiatry. 2010;67(2):109.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Omega-3s for Prodromal Psychosis
JWatch Psychiatry 2010;2010:2-2.
FULL TEXT
RAPID RESPONSES TO THIS ARTICLE
Fish Oil to Prevent Psychosis
Scott W Woods
Arch Gen Psychiatry Online, 23 Feb 2010.
TEXT
Omega-3 Fatty Acid Deficiency as a Risk Factor for Schizophrenia
Robert K. McNamara
Arch Gen Psychiatry Online, 9 Mar 2010.
TEXT
|
